Enspryng (satralizumab-mwge) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Satralizumab is a recombinant humanised monoclonal antibody that targets IL-6 receptor activity. Credit: Business Wire.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
